1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,915 | 0,946 | 18:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Cereno Scientific AB: Cereno Scientific shares the report from Annual General Meeting 2025 | 116 | GlobeNewswire (Europe) | Today, June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairman of the Annual General Meeting (the... ► Artikel lesen | |
| 27.05. | Cereno Scientific - Firing on all cylinders | 288 | Edison Investment Research | In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement... ► Artikel lesen | |
| 27.05. | Cereno Scientific is nominated and shortlisted for 'Company of the Year' in the European Mediscience Awards 2025 | 1 | Cision News | ||
| 23.05. | Cereno Scientific AB: Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH) | 120 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 22.05. | Cereno Scientific AB: Cereno Scientific publishes Interim Report for Q1 2025 (January 1 - March 31, 2025) | 157 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 15.05. | Cereno Scientific publishes Annual Report for 2024 | 1 | Cision News | ||
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 13.05. | Cereno Scientific presented CS1's Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025 | 2 | Cision News | ||
| 09.05. | Cereno Scientific give notice to attend the Annual General Meeting 2025 | 1 | Cision News | ||
| 07.05. | Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025 | 1 | Cision News | ||
| 07.05. | Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025 | 2 | Cision News | ||
| 07.05. | Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm | 1 | Cision News | ||
| 23.04. | Cereno Scientific - CS1 takes another step towards Phase IIb | 290 | Edison Investment Research | Cereno Scientific has successfully completed its planned Type C meeting with the FDA for lead asset CS1. The minutes from the meeting will be available after 30 days, but Cereno has indicated that the... ► Artikel lesen | |
| 22.04. | Cereno Scientific aligns with FDA on CS1 development | 3 | Cision News | ||
| 22.04. | Cereno Scientific AB: Cereno Scientific completes successful FDA meeting discussing further clinical development of drug candidate CS1 in rare disease PAH | 180 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 17.04. | Cereno Scientific - CS014 completes Phase I, path clears for Phase II | 357 | Edison Investment Research | Cereno Scientific has announced that its second clinical stage asset, CS014, has completed the Phase I safety study, with the conclusion of the second, multiple ascending dose (MAD) part of the trial... ► Artikel lesen | |
| 16.04. | CERENO SCIENTIFIC: Cereno completes CS014 trial ahead of June top-line data | 1 | Cision News | ||
| 16.04. | Cereno Scientific AB: Cereno Scientific reports that its Phase I trial of CS014 has been concluded and confirms that top-line results are anticipated in June 2025 | 140 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 14.04. | Cereno Scientific to attend BIO International Convention 2025 - largest and most comprehensive event for biotechnology | 1 | Cision News | ||
| 17.03. | Cereno Scientific AB: Cereno Scientific extends patent protection for drug candidate CS1 in the US and has filed to extend market exclusivity to 2045 | 312 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 12.03. | Cereno Scientific secures FDA meeting to advance its development of CS1 for the treatment of rare disease PAH | 3 | Cision News |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,00 | -0,22 % | BioNTech, Moderna und Co im Fokus: Kennedy greift durch | Nächster Paukenschlag in den USA: Gesundheitsminister Robert F. Kennedy Jr. hat alle Mitglieder eines Gremiums (ACIP) von Impfexperten der US- Seuchenbehörde CDC entlassen. Das geht aus einer Mitteilung... ► Artikel lesen | |
| QIAGEN | 40,680 | -0,01 % | Qiagen NV-Aktie gewinnt 1,15 Prozent (40,805 €) | Im Wertpapierhandel liegt die Aktie von Qiagen NV gegenwärtig im Plus. Das Wertpapier kostete zuletzt 40,81 Euro. Für die Aktie von Qiagen NV steht gegenwärtig ein Wertanstieg 1,15 Prozent zu Buche.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,920 | -4,84 % | HotStocks USA: TESLA, NVIDIA und RECURSION PHARMA stark gehandelt | ||
| CUREVAC | 4,848 | +0,46 % | Mega-Deal in der Biotech-Branche: BioNTech greift nach CureVac! | In einer wegweisenden Branchenfusion übernimmt BioNTech SE (Nasdaq: BNTX), Pionier der mRNA-Technologie und bekannt durch den COVID-19-Impfstoff, das deutsche Biotech-Unternehmen CureVac N.V. (Nasdaq:... ► Artikel lesen | |
| EVOTEC | 7,398 | -2,66 % | Aktie von Evotec legt um 2,55 Prozent zu (7,24 €) | An der deutschen Börse liegt die Aktie von Evotec derzeit im Plus. Der jüngste Kurs betrug 7,24 Euro. Ein Preisanstieg von 2,55 Prozent steht gegenwärtig für der Anteilsschein von Evotec zu Buche. Das... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,410 | -0,35 % | Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 31,370 | -2,40 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,780 | +0,04 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 15,390 | +6,88 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen | |
| MODERNA | 23,180 | -1,19 % | Zukunftsmarkt - hier geht es um 50 Mrd. USD: Illumina, Moderna, PanGenomic Health | Medizin wird persönlich. Die Zeit, in der Medikamente allen helfen sollen, naht ihrem Ende. Die Experten von BCC Research gehen davon aus, dass der Markt für personalisierte Medizin zwischen 2023 und... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 44,450 | +6,16 % | Apogee Therapeutics stock maintains buy rating ahead of key trial data | ||
| ENLIVEN THERAPEUTICS | 21,910 | +11,47 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,820 | -3,61 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,780 | -1,88 % | Why Summit Therapeutics Stock Tanked Today | ||
| TANGO THERAPEUTICS | 4,690 | -7,13 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors | BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen |
Das Unternehmen CERENO SCIENTIFIC AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,33 % bei einem Aktienkurs von 0,903 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.